Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020

  • ID: 3612127
  • Report
  • Region: Global
  • 87 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • MORE
The global hepatitis drugs market accounted for revenue of $23,222.1 million in 2014, and it is expected to grow with a CAGR of 29.7% during 2015 - 2020. Among the various types, the hepatitis C segment dominated the global hepatitis drugs market, with 76.1% share in 2014.

The global market of hepatitis drugs is up surging with a significant rate, due to increasing incidences of hepatitis, and increasing support from government organizations. Hepatitis is one of the leading causes of death around the world. According to the Hepatitis B Foundation, every year around 1 million deaths are recorded due to hepatitis B and its complications around the world. In the case of hepatitis C, the WHO stated that approximately 500,000 deaths are reported globally every year from hepatitis C related infections.

The increasing participation of various government organizations is leading to increasing awareness about various types of hepatitis infections and their management. Several government organizations are providing support, in form of funding and initiatives implemented by them for enhancing prevention, offering drug therapies, encouraging testing, and providing patient-centric services.

The major organizations include Centers for Disease Control and Prevention (CDC), WHO, U.S. Department of Health and Human Services (HHS), Hepatitis Foundation International, Immunization Action Coalition, and American Liver Foundation. Additionally, the growing geriatric population and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the market.

The aging population is increasing rapidly around the world. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with a very high rate. The number increased from a global share of 9.2% in 1990 to 11.7% in 2013, and is expected to reach 21.1% by the end of 2050.

The restraints associated with the growth of the global hepatitis drugs market include high capital expenditure and stringent regulatory requirements. The growing number of collaboration and partnerships is one of the latest trends observed in the market.

Geographically, North America is expected to maintain its dominance in the global market of hepatitis drugs during 2015 - 2020. This is due to increased awareness about various types of hepatitis infections and their management; and aging population in the region. In addition, the increasing R&D investments and improved healthcare infrastructures are also driving the growth of market in the region.

Europe is expected to witness marginal growth in the global market of hepatitis drugs in the near future. However, the Asian market of hepatitis drugs is expected to witness the highest growth globally, during the forecast period. This is mainly due to aging population, increasing prevalence of hepatitis, and improving healthcare infrastructure. According to WHO, most children (90%) are infected with the hepatitis A, before the age of 10 years in the developing countries, such as India and China, due to unhygienic practices and poor sanitary conditions.

The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • MORE
1. Research Scope & Methodology
1.1 Market Definition
1.2 Objective
1.3 Market Scope
1.3.1 Market Breakdown By Segment
1.3.2 Market Breakdown By Geography
1.4 Research Methodology And Sources

2. Executive Summary
2.1 Key Findings
2.2 Research Summary

3. Market Outlook
3.1 Introduction
3.2 Global Trend In Hepatitis Drugs Market
3.2.1 Increasing Number Of Collaborations And Partnerships
3.3 Factors Driving The Growth Of The Market And Its Impact On Market Forecast
3.3.1 Increasing Incidences Of Hepatitis
3.3.2 Increasing Support From Government Organizations
3.3.3 Growing Geriatric Population
3.3.4 Increasing R&D Investments In Hepatitis Research And Drug Discovery
3.3.5 Impact Analysis Of Drivers On Market Forecast
3.4 Factors Hindering The Market And Its Impact On Market Forecast
3.4.1 High Capital Expenditure
3.4.2 Stringent Regulatory Requirements
3.4.3 Impact Analysis Of Restraints On Market Forecast

4. Global Hepatitis Drugs Market Size And Forecast (2011-2020)
4.1 Global Hepatitis Drugs Market Breakdown By Type
4.2 Global Hepatitis Drugs Market Breakdown By Geography

5. Global Hepatitis Drugs Market Breakdown By Type
5.1 Hepatitis C Drugs Market
5.1.1 Hepatitis C Drugs Market Segmentation By Region
5.1.2 Hepatitis C Drugs Market Segmentation By Drugs
5.2 Hepatitis B Drugs Market
5.2.1 Hepatitis B Drugs Market Segmentation By Region
5.2.2 Hepatitis B Drugs Market Segmentation By Drugs
5.3 Hepatitis A Drugs Market
5.3.1 Hepatitis A Drugs Market Segmentation By Region

6. Global Hepatitis Drugs Market Breakdown By Geography
6.1 North America Hepatitis Drugs Market
6.1.1 North America Hepatitis Drugs Market Breakdown By Type
6.1.2 North America Hepatitis Drugs Market Breakdown By Country
6.2 Europe Hepatitis Drugs Market
6.2.1 Europe Hepatitis Drugs Market Breakdown By Type
6.2.2 Europe Hepatitis Drugs Market Breakdown By Country
6.3 Asia Hepatitis Drugs Market
6.3.1 Asia Hepatitis Drugs Market Breakdown By Type
6.3.2 Asia Hepatitis Drugs Market Breakdown By Country
6.4 Rest Of The World Hepatitis Drugs Market
6.4.1 Row Hepatitis Drugs Market Breakdown By Type

7. Pipeline Drugs For Hepatitis

8. Drug Approval Process In The .S. And Eu
8.1 Drug Approval Process In The U.S.
8.2 Drug Approval In The Eu

9. Competitive Positioning And Market Share Analysis
9.1 Porter's Five Forces Of Competitive Position Analysis
9.1.1 Bargaining Power Of Buyers
9.1.2 Bargaining Power Of Suppliers
9.1.3 Threat Of New Entrants
9.1.4 Intensity Of Rivalry
9.1.5 Threat Of Substitutes
9.2 Global Hepatitis Drugs Market Share Analysis

10. Company Profiles And Strategic Developments
10.1 Key Company Profiles
10.1.1 Gilead Sciences Inc.
10.1.1.1 Business Overview
10.1.1.2 Product And Service Offerings
10.1.2 F. Hoffmann-La Roche Ltd
10.1.2.1 Business Overview
10.1.2.2 Product And Service Offerings
10.1.3 Johnson & Johnson
10.1.3.1 Business Overview
10.1.3.2 Product And Services Offerings
10.1.4 Merck & Co., Inc.
10.1.4.1 Business Overview
10.1.4.2 Product And Service Offerings
10.1.5 Glaxosmithkline Plc
10.1.5.1 Business Overview
10.1.5.2 Product And Service Offerings
10.1.6 Abbvie Inc.
10.1.6.1 Business Overview
10.1.6.2 Product And Service Offerings
10.1.7 Novartis Ag
10.1.7.1 Business Overview
10.1.7.2 Product And Service Offerings
10.1.8 Bristol-Myers Squibb Company
10.1.8.1 Business Overview
10.1.8.2 Product And Service Offerings
10.1.9 Dynavax Technologies Corporation
10.1.9.1 Business Overview
10.1.9.2 Product And Service Offerings
10.1.10 Mitsubishi Tanabe Pharma Corporation
10.1.10.1 Business Overview
10.1.10.2 Product And Service Offerings
10.2 Strategic Developments In The Hepatitis Drugs Market
10.2.1 Mergers & Acquisitions
10.2.2 Collaborations & Partnerships
10.2.3 Marketing Authorization
10.2.4 Product Launch
10.2.5 Application Filling
10.2.6 Pipeline Newscast
10.2.7 Others

11. Appendix
11.1 List Of Abbreviations

List Of Tables
Table 1 Specific Primary And Secondary Sources Used For This Publication
Table 2 Global Hepatitis Drugs Market Snapshot
Table 3 Major Collaboration And Partnerships In Hepatitis Drugs Market (2015)
Table 4 Drivers For The Market: Impact Analysis
Table 5 Restraints For The Market: Impact Analysis
Table 6 Global Hepatitis Drugs Market Breakdown By Type, $M (2015-2020)
Table 7 Global Hepatitis Drugs Market Breakdown By Geography, $M (2015-2020)
Table 8 Global Hepatitis C Drugs Market Breakdown By Geography, $M (2015-2020)
Table 9 Global Hepatitis C Drugs Market Breakdown By Drugs, $M (2015-2020)
Table 10 Global Hepatitis B Drugs Market Breakdown By Geography, $M (2015-2020)
Table 11 Global Hepatitis B Drugs Market Breakdown By Drugs, $M (2015-2020)
Table 12 Global Hepatitis A Drugs Market Breakdown By Geography, $M (2015-2020)
Table 13 North America Hepatitis Drugs Market Breakdown By Type, $M (2015-2020)
Table 14 North America Hepatitis Drugs Market Breakdown By Country, $M (2015-2020)
Table 15 Europe Hepatitis Drugs Market Breakdown By Type, $M (2015-2020)
Table 16 Europe Hepatitis Drugs Market Breakdown By Country, $M (2015-2020)
Table 17 Asia Hepatitis Drugs Market Breakdown By Type, $M (2015-2020)
Table 18 Asia Hepatitis Drugs Market Breakdown By Country, $M (2015-2020)
Table 19 Row Hepatitis Drugs Market Breakdown By Type, $M (2015-2020)
Table 20 Drugs Under Development For Chronic Hepatitis B, 2015
Table 21 Clinical Trial Stages Of Hepatitis C Drugs, 2015
Table 22 Gilead Sciences Inc.- Key Facts
Table 23 F. Hoffmann-La Roche Ltd-Key Facts
Table 24 Johnson & Johnson-Key Facts
Table 25 Merck & Co., Inc.-Key Facts
Table 26 Glaxosmithkline Plc-Key Facts
Table 27 Abbvie Inc.-Key Facts
Table 28 Novartis Ag-Key Facts
Table 29 Bristol-Myers Squibb Company-Key Facts
Table 30 Dynavax Technologies Corporation Key Facts
Table 31 Mitsubishi Tanabe Pharma Corporation - Key Facts

List Of Figures
Fig 1 Research Scope For Global Hepatitis Drugs Market
Fig 2 Research Methodology For Global Hepatitis Drugs Market
Fig 3 Types Of Hepatitis
Fig 4 Major Symptoms Of Hepatitis
Fig 5 Diagnotsic Procedures For Hepatitis
Fig 6 Key Drugs Used To Treat Hepatitis B And Hepatitis C
Fig 7 Aging Population As A Percentage Of Total Population In Major Countries
Fig 8 Basic Drug Development Procedure
Fig 9 Global Hepatitis Drugs Market Size By Type, $M (2014-2020)
Fig 10 Global Hepatitis Drugs Market Size By Geography, $M (2014-2020)
Fig 11 Global Hepatitis C Drugs Market Size, $M (2014-2020)
Fig 12 Global Hepatitis C Drugs Market Share, By Region (2014 And 2020)
Fig 13 Global Hepatitis C Drugs Market Size By Region, $M (2014-2020)
Fig 14 Global Hepatitis C Drugs Market Size By Drugs, $M (2014-2020)
Fig 15 Global Hepatitis B Drugs Market Size, $M (2014-2020)
Fig 16 Global Hepatitis B Drugs Market Share, By Region (2014 And 2020)
Fig 17 Global Hepatitis B Drugs Market Size By Region, $M (2014-2020)
Fig 18 Global Hepatitis B Drugs Market Size By Drugs, $M (2014-2020)
Fig 19 Global Hepatitis A Drugs Market Size, $M (2014-2020)
Fig 20 Global Hepatitis A Drugs Market Share, By Region (2014 And 2020)
Fig 21 Global Hepatitis A Drugs Market Size By Region, $M (2014-2020)
Fig 22 Global Hepatitis Drugs Market Size, By Geography
Fig 23 North America Hepatitis Drugs Market Size, $M (2014-2020)
Fig 24 North America Hepatitis Drugs Market Share, By Type (2014 And 2020)
Fig 25 North America Hepatitis Drugs Market Share, By Country (2014 And 2020)
Fig 26 Europe Hepatitis Drugs Market Size, $M (2014-2020)
Fig 27 Europe Hepatitis Drugs Market Share, By Type (2014 And 2020)
Fig 28 Europe Hepatitis Drugs Market Share, By Country (2014 And 2020)
Fig 29 Asia Hepatitis Drugs Market Size, $M (2014-2020)
Fig 30 Asia Hepatitis Drugs Market Share, By Type (2014 And 2020)
Fig 31 Asia Hepatitis Drugs Market Share, By Country (2014 And 2020)
Fig 32 Row Hepatitis Drugs Market Size, $M (2014-2020)
Fig 33 Row Hepatitis Drugs Market Share, By Type (2014 And 2020)
Fig 34 Porter’S Five Forces Of Competitive Position Analysis
Fig 35 Market Share Of Key Players In The Global Hepatitis Drugs Market (2014)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Gilead Sciences Inc.
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Merck & Co., Inc.
- GlaxoSmithKline plc
- AbbVie Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Dynavax Technologies Corporation
- Mitsubishi Tanabe Pharma Corporation
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll